aripiprazole has been researched along with paliperidone palmitate in 88 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 59 (67.05) | 24.3611 |
| 2020's | 29 (32.95) | 2.80 |
| Authors | Studies |
|---|---|
| Manoj, P; Skopek, M | 1 |
| Hara, C; Ramos, MG; Rocha, FL | 1 |
| Brunetti, L; Patel, MK | 1 |
| Atallah, AN; Melnik, T; Puga, ME; Soares, BG | 1 |
| Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA | 1 |
| Lai, CH | 1 |
| Knoepflmacher, D; Shapley, L; Turner, EH | 1 |
| Campistol, J; Darling, A; Perez-Duenas, B; Poo, P | 1 |
| Couchman, L; Fisher, DS; Flanagan, RJ; Handley, SA; Morgan, PE; Partridge, SJ | 1 |
| Fisher, DS; Flanagan, RJ; Handley, SA; Partridge, SJ | 1 |
| Medvedovici, A; Rădulescu, FŞ; Ranetti, AE; Voicu, V | 1 |
| Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L | 1 |
| Dai, G; Zhang, Y | 1 |
| Baker, RA; Bentley, TG; Citrome, L; Eramo, A; Gutierrez, B; Hansen, K; Kamat, SA; Ortendahl, J; Sapin, C | 1 |
| Budman, CL | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Cortese, S | 1 |
| Gopal, S; Hough, D; Lane, R; Nuamah, I; Savitz, AJ | 1 |
| Bjelobaba, I; Budimirovic, DB; Kucka, M; Stojilkovic, SS; Tomić, M | 1 |
| Andersen, HS; Baker, RA; Beillat, M; Eramo, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C | 1 |
| Jiang, Y; Ni, W | 1 |
| Bereza, BG; Einarson, TR; Goswami, P; Pudas, H; van Impe, K | 1 |
| Bernard, S; Hugo, N; Kristof, M; Lisbeth, P; Manuel, M; Vincent, H | 1 |
| Chue, J; Chue, P | 1 |
| Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M | 1 |
| Guo, Q; Li, C; Ouyang, Q; Qiao, Y; Shen, W; Sheng, J; Wen, H; Yang, F; Zhu, S | 1 |
| Ariyawansa, J; De Meulder, M; Remmerie, B; Savitz, A | 1 |
| De Meulder, M; Remmerie, B; Savitz, A; Weiner, S | 1 |
| Akpek, M; Avcil, M; Kantekin, B; Kapçı, M; Yavaşoğlu, I | 1 |
| Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL | 1 |
| Bergmans, P; Caspi, A; Cherubin, P; Hargarter, L; Keim, S; Lara, E; Pinchuk, I; Schreiner, A; Schuepbach, D; Suleman, S | 1 |
| Baker, RA; Beillat, M; Eramo, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nitschky Schmidt, S; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C | 1 |
| Citrome, L | 1 |
| Li, Y; Wang, ST | 1 |
| Baker, RA; Beillat, M; Eramo, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C; Steen Andersen, H | 1 |
| Bahk, WM; Emsley, R; Han, C; Lee, SJ; Masand, PS; Pae, CU; Patkar, AA; Serretti, A; Wang, SM | 1 |
| Baker, RA; Beillat, M; Eramo, A; Ettrup, A; Forray, C; Hansen, K; Hertel, P; Loze, JY; Naber, D; Nitschky Schmidt, S; Nylander, AG; Peters-Strickland, T; Potkin, SG; Sapin, C | 1 |
| Emond, B; Joshi, K; Kamstra, R; Lafeuille, MH; Lefebvre, P; Pilon, D; Tandon, N | 1 |
| Fujita, Y; Nagamine, T; Nakamura, M | 1 |
| Baeza, I; de Castro, C; Espinosa, L; Fortea, A; Ilzarbe, D; Oriolo, G; Solerdelcoll, M; Sugranyes, G | 1 |
| Huang, HC; Motamarri, B; Taylor, M; Theodoros, T; Wang, N | 1 |
| Berlin, J; Gopal, S; Kern-Sliwa, J; Kim, E; Mathews, M; Singh, A; Turkoz, I; Wooller, A | 1 |
| Hibino, H; Inoue, Y; Suzuki, H; Takaya, A | 3 |
| Augusto, M; Greene, M; Sweeney, SM; Touya, M; Waters, H | 2 |
| Landry, P; Michaud, I | 1 |
| Carvalho, AF; Hidalgo-Mazzei, D; Murru, A; Pacchiarotti, I; Samalin, L; Verdolini, N; Vieta, E; Young, AH | 1 |
| Ballerini, A; Brugnoli, R; Carrus, D; Comparelli, A; De Filippis, S; Del Casale, A; Ducci, G; Francomano, A; Girardi, P; Kotzalidis, GD; Mancinelli, I; Marcellusi, A; Mennini, FS; Pompili, M; Rapinesi, C; Sani, G; Sorice, S; Splendori, F; Trovini, G; Verzura, C | 1 |
| Brakoulias, V; Stockings, E | 1 |
| Li, FL; Liang, CS; Yang, FC; Yeh, TC | 1 |
| Doz, M; Gozlan, G; Lafuma, A; Larroumets, P; Lecardeur, L; Monfort, AS; Ortiz, I | 1 |
| Claxton, A; Du, Y; Miller, BJ; Potkin, SG; Weiden, PJ | 1 |
| Cai, Q; Connolly, N; El Khoury, AC; Kim, E; Patel, C; Tunceli, O | 1 |
| Brouillette, M; El Khoury, AC; Joshi, K; Smith, D; Song, X | 1 |
| Hatano, M; Inagaki, R; Kamei, H; Taniguchi, M; Yamada, S | 1 |
| Hernandez, R; Lertxundi, U; Medrano, J | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Broder, MS; Chang, E; Greene, M; Houle, CR; Tarbox, MH; Waters, HC; Yan, T | 1 |
| Aloi, M; De Fazio, P; de Filippis, R; Gaetano, R; Magliocco, F; Segura-Garcia, C; Staltari, FA | 1 |
| Cattaneo, D; Franco, G; Mauri, MC; Minutillo, A; Pace, CD; Paletta, S; Reggiori, A | 1 |
| Barbui, C; Bartoli, F; Carrà, G; Corbo, M; Crocamo, C; D'Agostino, A; Martinotti, G; Ostinelli, EG; Ostuzzi, G; Tabacchi, T | 1 |
| Le, J; Li, Y; Wang, S; Yuan, T | 1 |
| Bidollari, I; Cash, E; Claxton, A; Du, Y; Keane, E; Kunovac, J; Walling, DP; Weiden, PJ; Yagoda, S; Yao, B | 1 |
| Dobson, L; Grace, T; Hacking, D; Jolly, N; Kapi, P; Parmar, A; Shymko, G; Waters, F | 1 |
| Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P | 1 |
| Arnaiz, A; Arrue, A; Basterreche, N; Erkoreka, L; González-Torres, MA; Olivas, O; Zamalloa, MI; Zumárraga, M | 1 |
| Barbui, C; Bertolini, F; Bovo, C; Correll, CU; Del Giovane, C; Gastaldon, C; Nosé, M; Ogheri, F; Ostuzzi, G; Papola, D; Purgato, M; Tedeschi, F; Turrini, G | 1 |
| Bidollari, I; Claxton, A; Du, Y; Kelly, DL | 1 |
| Shimoda, K; Shinozaki, M; Sugawara, N; Tasaki, M; Yasui-Furukori, N; Yokoyama, S | 1 |
| Hatano, M; Iwata, N; Kishi, T; Okuya, M; Sakuma, K | 1 |
| Kyziridis, TC | 1 |
| Claxton, A; Du, Y; Nasrallah, HA; Walling, DP; Weiden, PJ; Yagoda, S; Yao, B | 1 |
| Fujita, K; Iga, JI; Inada, K; Ishigooka, J; Iwata, N; Kanda, Y; Kikuchi, Y; Kishi, T; Kishimoto, T; Koretsune, S; Nakagome, K; Ohi, K; Ohmori, T; Sekiyama, K; Shichijo, T; Tabuse, H; Terada, H; Tsutsumi, Y | 1 |
| Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Nomura, I; Okuya, M; Sakuma, K | 1 |
| Hibino, H; Suzuki, H | 1 |
| Barbui, C; Bartoli, F; Bertolini, F; Callovini, T; Carrà, G; Cavaleri, D; Crocamo, C; D'Agostino, A; Martinotti, G; Ostuzzi, G; Riboldi, I | 1 |
| García Dorado, M; Gutiérrez-Rojas, L; López Rengel, PM; Sánchez-Alonso, S | 1 |
| Byeon, SJ; Chung, SJ; Oh, S | 1 |
| Beck, M; Gitahy Falcao Faria, C; Javelot, H; Meyer, G; Michel, B; Riutort, M | 1 |
| Osman, E; Yıldız, M | 1 |
| Arango, C; Leucht, S; Lopez-Morinigo, JD | 1 |
| Fujii, Y; Misawa, F; Takeuchi, H | 1 |
| Cao, D; Hong, Y; Huang, W; Wang, L; Wei, H; Xu, J; Zhang, J | 1 |
| Anam, A; Gekhman, D; Lynch, S; Mosharraf, N; Soukas, C | 1 |
| Akazawa, M; Inada, K; Okada, Y | 1 |
18 review(s) available for aripiprazole and paliperidone palmitate
| Article | Year |
|---|---|
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews.
Topics: Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Humans; Isoxazoles; Meta-Analysis as Topic; Paliperidone Palmitate; Piperazines; Placebos; Pyrimidines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Review Literature as Topic; Risperidone; Schizophrenia; Treatment Outcome | 2010 |
[Medication-related oculogyric crises: a description of four cases and a review of the literature].
Topics: Adolescent; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Child; Child Behavior Disorders; Child, Preschool; Dopamine; Dopamine Antagonists; Down Syndrome; Dyskinesia, Drug-Induced; Dystonic Disorders; Electroencephalography; Epilepsy; Female; Fragile X Syndrome; Humans; Intellectual Disability; Isoxazoles; Male; Methotrimeprazine; Ocular Motility Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Risperidone; Substance Withdrawal Syndrome; Translocation, Genetic; Valproic Acid | 2013 |
Drug-induced hypo- and hyperprolactinemia: mechanisms, clinical and therapeutic consequences.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Blood-Brain Barrier; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Prolactin; Pyrimidines; Quinolones; Receptors, Dopamine D2; Risperidone; Stress, Psychological; Sulpiride; Xenobiotics | 2013 |
The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Humans; Isoxazoles; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Risperidone; Tourette Syndrome; Treatment Outcome | 2014 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
A review of aripiprazole long-acting injection.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Hospitalization; Humans; Paliperidone Palmitate; Quality of Life; Schizophrenia | 2016 |
Emerging pharmacological therapies in schizophrenia: what's new, what's different, what's next?
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Injections, Intramuscular; Paliperidone Palmitate; Piperazines; Quinolones; Schizophrenia; Tetrabenazine; Thiophenes; Valine | 2016 |
Comparison between long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia: systematic review and indirect treatment comparison.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Humans; Injections, Intramuscular; Paliperidone Palmitate; Schizophrenia; Treatment Outcome | 2017 |
Going the distance: reviewing antipsychotic depot or long-acting injectable treatments in Australasia.
Topics: Antipsychotic Agents; Aripiprazole; Australia; Delayed-Action Preparations; Humans; Mental Disorders; Paliperidone Palmitate | 2018 |
Mixed states in bipolar and major depressive disorders: systematic review and quality appraisal of guidelines.
Topics: Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Electroconvulsive Therapy; Humans; Lithium; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Practice Guidelines as Topic; Quetiapine Fumarate; Thiazoles; Valproic Acid | 2018 |
A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Obsessive-Compulsive Disorder; Paliperidone Palmitate; Risperidone; Selective Serotonin Reuptake Inhibitors; Treatment Outcome | 2019 |
[Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; France; Humans; Paliperidone Palmitate; Quality of Life; Schizophrenia; Schizophrenic Psychology | 2018 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis.
Topics: Antipsychotic Agents; Aripiprazole; Clopenthixol; Delayed-Action Preparations; Flupenthixol; Fluphenazine; Haloperidol; Humans; Injections, Intramuscular; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Patient Acceptance of Health Care; Phenothiazines; Psychotic Disorders; Risperidone; Schizophrenia; Secondary Prevention | 2021 |
[Clinical pharmacokinetics and pharmaceutical forms of long-acting injectable antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Olanzapine; Paliperidone Palmitate; Risperidone | 2022 |
Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Carbamazepine; Female; Haloperidol; Humans; Lithium; Male; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Tamoxifen; Valproic Acid | 2022 |
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lurasidone Hydrochloride; Molindone; Olanzapine; Paliperidone Palmitate; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Systematic Reviews as Topic | 2022 |
A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Carbamazepine; Dibenzocycloheptenes; Haloperidol; Humans; Lithium; Mania; Network Meta-Analysis; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Piperazines; Quetiapine Fumarate; Risperidone; Tamoxifen; Thiazoles; Valproic Acid | 2022 |
12 trial(s) available for aripiprazole and paliperidone palmitate
| Article | Year |
|---|---|
Efficacy and metabolic influence of paliperidone ER, aripiprazole and ziprasidone to patients with first-episode schizophrenia through 52 weeks follow-up in China.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; China; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Female; Follow-Up Studies; Humans; Hyperglycemia; Hyperlipidemias; Isoxazoles; Male; Metabolic Diseases; Paliperidone Palmitate; Piperazines; Psychiatric Status Rating Scales; Pyrimidines; Quinolones; Schizophrenia; Thiazoles; Weight Gain; Young Adult | 2012 |
Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Delayed-Action Preparations; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Europe; Female; Headache; Humans; India; Male; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychomotor Agitation; Schizophrenia; Severity of Illness Index; Treatment Outcome; United States; Weight Gain | 2015 |
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Least-Squares Analysis; Male; Paliperidone Palmitate; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Single-Blind Method; Treatment Outcome | 2015 |
Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Clopenthixol; Cytochrome P-450 CYP2D6; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Haloperidol; Humans; Male; Middle Aged; Paliperidone Palmitate; Young Adult | 2016 |
Comparison of Capillary and Venous Drug Concentrations After Administration of a Single Dose of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Specimen Collection; Capillaries; Female; Fingers; Half-Life; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Veins; Young Adult | 2016 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2016 |
Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Employment; Female; Humans; Male; Paliperidone Palmitate; Patient Satisfaction; Psychiatric Status Rating Scales; Quality of Life; Schizophrenia; Severity of Illness Index; Single-Blind Method; Surveys and Questionnaires; Treatment Outcome | 2017 |
Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Prolactin; Quality of Life; Schizophrenia; Sexual Dysfunction, Physiological; Young Adult | 2017 |
Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Drug Costs; Female; Humans; Injections, Intramuscular; Male; Markov Chains; Middle Aged; Paliperidone Palmitate; Piperazines; Quality-Adjusted Life Years; Risperidone; Schizophrenia; Young Adult | 2018 |
Efficacy and Safety of a 2-Month Formulation of Aripiprazole Lauroxil With 1-Day Initiation in Patients Hospitalized for Acute Schizophrenia Transitioned to Outpatient Care: Phase 3, Randomized, Double-Blind, Active-Control ALPINE Study.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Double-Blind Method; Hospitalization; Humans; Injections, Intramuscular; Middle Aged; Paliperidone Palmitate; Patient Discharge; Schizophrenia; Young Adult | 2020 |
Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Patient Reported Outcome Measures; Quality of Life; Schizophrenia; Treatment Outcome | 2021 |
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics: 52-week evaluation of JUMPs, a randomized, open-label study.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Piperazines; Piperidines; Remission Induction; Schizophrenia; Social Interaction; Treatment Outcome | 2022 |
58 other study(ies) available for aripiprazole and paliperidone palmitate
| Article | Year |
|---|---|
Hyperprolactinaemia during treatment with paliperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dibenzothiazepines; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Monitoring; Female; Galactorrhea; Humans; Hyperprolactinemia; Isoxazoles; Middle Aged; Paliperidone Palmitate; Patient Compliance; Piperazines; Prolactin; Psychotic Disorders; Pyrimidines; Quetiapine Fumarate; Quinolones; Recurrence; Schizophrenia, Paranoid; Young Adult | 2010 |
Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Humans; Hyperprolactinemia; Isoxazoles; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2010 |
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2010 |
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Isoxazoles; Movement Disorders; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2011 |
Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Databases, Factual; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Publication Bias; Pyrimidines; Quetiapine Fumarate; Quinolones; Risperidone; United States; United States Food and Drug Administration | 2012 |
LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cattle; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Drug Stability; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Humans; Hypochondriasis; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Paliperidone Palmitate; Prevalence; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride | 2014 |
Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States.
Topics: Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Decision Support Techniques; Drug Administration Schedule; Humans; Injections, Intramuscular; Isoxazoles; Paliperidone Palmitate; Palmitates; Piperazines; Quinolones; Schizophrenia; United States | 2014 |
Here/In this issue and there/abstract thinking: trials in child psychiatry: and now … be more pragmatic, please!
Topics: Adolescent; Aripiprazole; Bipolar Disorder; Child; Child Psychiatry; Child Rearing; Cognitive Behavioral Therapy; Humans; Paliperidone Palmitate; Periodicals as Topic; Pragmatic Clinical Trials as Topic; Schizophrenia | 2015 |
Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs.
Topics: Animals; Aripiprazole; Calcium Signaling; Dopamine; Female; Humans; Hyperprolactinemia; Lactotrophs; Paliperidone Palmitate; Prolactin; Rats; Schizophrenia; Signal Transduction | 2015 |
Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Aripiprazole; Cohort Studies; Drug Costs; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Patient Acceptance of Health Care; Retrospective Studies; Schizophrenia | 2015 |
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Economics, Pharmaceutical; Female; Finland; Humans; Male; Olanzapine; Paliperidone Palmitate; Risperidone; Schizophrenia | 2016 |
Two long-acting injectable antipsychotics for schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Double-Blind Method; Humans; Injections; Paliperidone Palmitate; Schizophrenia; United States; United States Food and Drug Administration | 2015 |
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, Intramuscular; Markov Chains; Models, Economic; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; State Medicine; United Kingdom | 2015 |
Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Estradiol; Female; Humans; Hyperprolactinemia; Middle Aged; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2016 |
Comparison of Capillary and Venous Plasma Drug Concentrations After Repeated Administration of Risperidone, Paliperidone, Quetiapine, Olanzapine, or Aripiprazole.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Specimen Collection; Capillaries; Female; Fingers; Half-Life; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Veins; Young Adult | 2016 |
Simultaneous Use of Intravenous Lipid Emulsion and Plasma Exchange Therapies in Multiple Drug Toxicity.
Topics: Amisulpride; Antihypertensive Agents; Antipsychotic Agents; Aripiprazole; Diazepam; Drug-Related Side Effects and Adverse Reactions; Fat Emulsions, Intravenous; Female; Humans; Hypnotics and Sedatives; Hypotension; Middle Aged; Paliperidone Palmitate; Plasma Exchange; Suicide, Attempted; Sulpiride; Treatment Outcome; Turkey; Valsartan | 2016 |
Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Drug Substitution; Female; Humans; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Patient Satisfaction; Prospective Studies; Risperidone; Schizophrenia; Surveys and Questionnaires; Treatment Outcome | 2017 |
Development of a UPLC-MS/MS method for routine therapeutic drug monitoring of aripiprazole, amisulpride, olanzapine, paliperidone and ziprasidone with a discussion of their therapeutic reference ranges for Chinese patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; China; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Limit of Detection; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Reference Values; Tandem Mass Spectrometry; Thiazoles; Young Adult | 2017 |
Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy, Combination; Employment; Female; Humans; Male; Middle Aged; Paliperidone Palmitate; Schizophrenia | 2017 |
Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
Topics: Administration, Oral; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cost Savings; Delayed-Action Preparations; Female; Health Care Costs; Hospitalization; Humans; Injections; Long-Term Care; Male; Medicaid; Medication Adherence; Middle Aged; Olanzapine; Paliperidone Palmitate; Practice Patterns, Physicians'; Risperidone; Schizophrenia; United States; Young Adult | 2017 |
Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient.
Topics: Antipsychotic Agents; Aripiprazole; Biomarkers; Humans; Male; Middle Aged; Paliperidone Palmitate; Prolactin; Schizophrenia; Treatment Outcome | 2018 |
Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Child; Delayed-Action Preparations; Female; Hospitalization; Humans; Inpatients; Male; Off-Label Use; Paliperidone Palmitate; Psychiatric Status Rating Scales; Psychotic Disorders; Retrospective Studies; Risperidone; Treatment Outcome | 2018 |
Methodological challenges in indirect treatment comparisons: spotlight on a recent comparison of long-acting injectable aripiprazole versus paliperidone palmitate in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Paliperidone Palmitate; Reproducibility of Results; Schizophrenia; Treatment Outcome | 2018 |
Changes in length of hospital stay and number of hospitalization before and after the administration of three second-generation antipsychotics long-acting injections in patients with schizophrenia: Mirror-image study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Hospitalization; Humans; Length of Stay; Male; Paliperidone Palmitate; Risperidone; Schizophrenia; Treatment Outcome | 2018 |
Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Budgets; Cost-Benefit Analysis; Delayed-Action Preparations; Dibenzocycloheptenes; Drug Administration Schedule; Drug Costs; Health Care Costs; Heterocyclic Compounds, 4 or More Rings; Hospitalization; Humans; Injections, Intramuscular; Injections, Subcutaneous; Medication Adherence; Paliperidone Palmitate; Piperazines; Schizophrenia | 2018 |
Case Report: Paliperidone Palmitate, But Not Aripiprazole, as a Possible Risk Factor for Pulmonary Embolism.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Paliperidone Palmitate; Pulmonary Embolism; Young Adult | 2018 |
Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Young Adult | 2018 |
Comparisons of the effects of second-generation antipsychotics long-acting injections on treatment retention according to severity of patient condition.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Injections; Japan; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index | 2018 |
Treatment Continuation of 3 Second-Generation Antipsychotic Long-Acting Injections, and Oral Paliperidone in Patients With Schizophrenia for 2 Years.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Cohort Studies; Delayed-Action Preparations; Drug Therapy, Combination; Female; Humans; Injections; Male; Middle Aged; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia; Treatment Outcome | 2018 |
Combined typical and atypical long-acting injectable antipsychotics in treatment-resistant schizophrenia: Two cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Therapy, Combination; Female; Flupenthixol; Humans; Male; Middle Aged; Paliperidone Palmitate; Schizophrenia; Treatment Outcome | 2019 |
Switching patients with schizophrenia from paliperidone palmitate to aripiprazole lauroxil: A 6-month, prospective, open-label study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Substitution; Female; Humans; Injections; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Prospective Studies; Schizophrenia | 2019 |
Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Drug Utilization Review; Female; Humans; Injections; Male; Medicaid; Paliperidone Palmitate; Patient Selection; Practice Patterns, Physicians'; Schizophrenia; United States | 2019 |
Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
Topics: Administration, Oral; Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Comorbidity; Delayed-Action Preparations; Female; Humans; Injections, Intramuscular; Insurance Claim Review; Kaplan-Meier Estimate; Longitudinal Studies; Male; Medicaid; Medication Adherence; Middle Aged; Paliperidone Palmitate; Proportional Hazards Models; Racial Groups; Retrospective Studies; Risperidone; Schizophrenia; Sex Factors; United States | 2019 |
Factors That Affect Continuation of Antipsychotic Long-Acting Injections.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Male; Medication Adherence; Middle Aged; Paliperidone Palmitate; Risperidone; Schizophrenia | 2019 |
The impact of the ambiguous definition of "month" on pharmacotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Drug Administration Schedule; Drug Therapy; Humans; Medication Adherence; Models, Theoretical; Paliperidone Palmitate; Schizophrenia; Software; Spain; Time | 2019 |
Health Care Cost in Patients With Schizophrenia Treated With Brexpiprazole Versus Other Oral Atypical Antipsychotic Therapy.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Female; Health Care Costs; Hospitalization; Humans; Lurasidone Hydrochloride; Male; Medicaid; Medicare; Middle Aged; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles; Thiophenes; United States | 2020 |
Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cognitive Dysfunction; Delayed-Action Preparations; Executive Function; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paliperidone Palmitate; Prospective Studies; Schizophrenia | 2020 |
Paliperidone LAI and Aripiprazole LAI Plasma Level Monitoring in the Prophylaxis of Bipolar Disorder Type I with Manic Predominance.
Topics: Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Delayed-Action Preparations; Depression; Female; Humans; Injections; Male; Mania; Middle Aged; Paliperidone Palmitate; Prospective Studies; Psychiatric Status Rating Scales; Treatment Outcome; Young Adult | 2020 |
Clinical correlates of paliperidone palmitate and aripiprazole monohydrate prescription for subjects with schizophrenia-spectrum disorders: findings from the STAR Network Depot Study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Female; Health Knowledge, Attitudes, Practice; Humans; Male; Medication Adherence; Paliperidone Palmitate; Practice Patterns, Physicians'; Schizophrenia; Schizophrenic Psychology; Young Adult | 2020 |
Effects of Atypical Antipsychotics on Neuroactive Vitamins in Patients With Schizophrenia.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Case-Control Studies; Female; Humans; Male; Olanzapine; Paliperidone Palmitate; Schizophrenia; Vitamin A; Vitamin D; Vitamin E; Vitamins; Young Adult | 2020 |
Weight gain and metabolic screening in young people with early psychosis on long acting injectable antipsychotic medication (aripiprazole vs paliperidone).
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Psychotic Disorders; Schizophrenia; Weight Gain | 2021 |
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Humans; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Substance Abuse Detection; Suicide; Sulpiride; Tandem Mass Spectrometry; Thiazoles | 2020 |
Factors influencing the effect of aripiprazole on prolactin levels in patients treated with risperidone or paliperidone. Sex seems to matter.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Prolactin; Risperidone | 2021 |
Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil.
Topics: Antipsychotic Agents; Aripiprazole; Female; Humans; Hyperprolactinemia; Male; Paliperidone Palmitate; Prolactin; Prospective Studies; Schizophrenia | 2021 |
Hypoprolactinemia and hyperprolactinemia in male schizophrenia patients treated with aripiprazole and risperidone and their relationships with testosterone levels.
Topics: Antipsychotic Agents; Aripiprazole; Female; Genetic Diseases, Inborn; Humans; Hyperprolactinemia; Lactation Disorders; Male; Paliperidone Palmitate; Prolactin; Risperidone; Schizophrenia; Testosterone | 2021 |
Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Schizophrenia | 2021 |
Comparison of treatment retention between risperidone long-acting injection, paliperidone palmitate, and aripiprazole once-monthly in elderly patients with schizophrenia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Risperidone; Schizophrenia | 2022 |
Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Prospective Studies; Schizophrenia | 2022 |
Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Humans; Paliperidone Palmitate; Recurrence; Retrospective Studies; Schizophrenia; Spain | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia | 2022 |
Suicidality and psychotic episodes after starting aripiprazole: two case reports.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Male; Paliperidone Palmitate; Risperidone; Suicide | 2022 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |
Tardive Dyskinesia and Long-Acting Injectable Antipsychotics: Analyses Based on a Spontaneous Reporting System Database in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Japan; Paliperidone Palmitate; Risperidone; Schizophrenia; Tardive Dyskinesia | 2022 |
Aripiprazole: examining the clinical implications of D2 affinity.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Paliperidone Palmitate; Risperidone; Schizophrenia | 2023 |
Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
Topics: Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Fluphenazine; Haloperidol; Humans; Japan; Paliperidone Palmitate; Retrospective Studies; Risperidone; Schizophrenia | 2023 |